Gravastrand Caroline, Hamad Shamal, Fure Hilde, Steinkjer Bjørg, Ryan Liv, Oberholzer Josè, Lambris John D, Lacík Igor, Mollnes Tom Eirik, Espevik Terje, Brekke Ole-Lars, Rokstad Anne Mari
Centre of Molecular Inflammation Research, and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Research Laboratory, Nordland Hospital, 8092 Bodø, Norway.
Acta Biomater. 2017 Aug;58:158-167. doi: 10.1016/j.actbio.2017.05.052. Epub 2017 May 30.
Alginate microspheres are presently under evaluation for future cell-based therapy. Their ability to induce harmful host reactions needs to be identified for developing the most suitable devices and efficient prevention strategies. We used a lepirudin based human whole blood model to investigate the coagulation potentials of alginate-based microspheres: alginate microbeads (Ca/Ba Beads), alginate poly-l-lysine microcapsules (APA and AP microcapsules) and sodium alginate-sodium cellulose sulfate-poly(methylene-co-cyanoguanidine) microcapsules (PMCG microcapsules). Coagulation activation measured by prothrombin fragments 1+2 (PTF1.2) was rapidly and markedly induced by the PMCG microcapsules, delayed and lower induced by the APA and AP microcapsules, and not induced by the Ca/Ba Beads. Monocytes tissue factor (TF) expression was similarly activated by the microcapsules, whereas not by the Ca/Ba Beads. PMCG microcapsules-induced PTF1.2 was abolished by FXII inhibition (corn trypsin inhibitor), thus pointing to activation through the contact pathway. PTF1.2 induced by the AP and APA microcapsules was inhibited by anti-TF antibody, pointing to a TF driven coagulation. The TF induced coagulation was inhibited by the complement inhibitors compstatin (C3 inhibition) and eculizumab (C5 inhibition), revealing a complement-coagulation cross-talk. This is the first study on the coagulation potentials of alginate microspheres, and identifies differences in activation potential, pathways and possible intervention points.
Alginate microcapsules are prospective candidate materials for cell encapsulation therapy. The material surface must be free of host cell adhesion to ensure free diffusion of nutrition and oxygen to the encapsulated cells. Coagulation activation is one gateway to cellular overgrowth through deposition of fibrin. Herein we used a physiologically relevant whole blood model to investigate the coagulation potential of alginate microcapsules and microbeads. The coagulation potentials and the pathways of activation were depending on the surface properties of the materials. Activation of the complement system could also be involved, thus emphasizing a complement-coagulation cross-talk. Our findings points to complement and coagulation inhibition as intervention point for preventing host reactions, and enhance functional cell-encapsulation devices.
藻酸盐微球目前正在接受评估,以用于未来基于细胞的治疗。在开发最合适的装置和有效的预防策略时,需要确定它们诱导有害宿主反应的能力。我们使用基于水蛭素的人全血模型来研究藻酸盐基微球的凝血潜能:藻酸盐微珠(钙/钡珠)、藻酸盐聚-L-赖氨酸微胶囊(APA和AP微胶囊)以及藻酸钠-硫酸纤维素钠-聚(亚甲基-co-氰基胍)微胶囊(PMCG微胶囊)。通过凝血酶原片段1+2(PTF1.2)测量的凝血激活在PMCG微胶囊作用下迅速且显著地诱导产生,在APA和AP微胶囊作用下延迟且诱导程度较低,而在钙/钡珠作用下未诱导产生。单核细胞组织因子(TF)表达在微胶囊作用下同样被激活,而在钙/钡珠作用下未被激活。FXII抑制(玉米胰蛋白酶抑制剂)可消除PMCG微胶囊诱导的PTF1.2,因此表明是通过接触途径激活。AP和APA微胶囊诱导的PTF1.2被抗TF抗体抑制,表明是由TF驱动的凝血。TF诱导的凝血被补体抑制剂compstatin(C3抑制)和依库珠单抗(C5抑制)抑制,揭示了补体-凝血相互作用。这是关于藻酸盐微球凝血潜能的首次研究,并确定了激活潜能、途径和可能的干预点的差异。
藻酸盐微胶囊是细胞封装治疗的潜在候选材料。材料表面必须无宿主细胞粘附,以确保营养物质和氧气向封装细胞的自由扩散。凝血激活是通过纤维蛋白沉积导致细胞过度生长的一个途径。在此,我们使用生理相关的全血模型来研究藻酸盐微胶囊和微珠的凝血潜能。凝血潜能和激活途径取决于材料的表面性质。补体系统的激活也可能参与其中,从而强调了补体-凝血相互作用。我们的研究结果指出补体和凝血抑制作为预防宿主反应的干预点,并改进功能性细胞封装装置。